Background

Awarded her PhD at Monash University, Professor Tachedjian received an NHMRC CJ Martin Fellowship to undertake postdoctoral studies at Columbia University in New York with Professor Stephen Goff on retroviral replication.

In 2002, Professor Tachedjian was recruited to Burnet Institute. She was awarded an NHMRC RD Wright Career Development Award in 2003 and an NHMRC Senior Research Fellowship’s in 2009 and in 2017.

A virologist combining interdisciplinary basic, translational and clinical research to identify and develop effective drug-based strategies to prevent and control emerging pathogens including human immunodeficiency virus (HIV). She has made major contributions to HIV reverse transcriptase, antivirals, drug resistance and HIV prevention research. She was awarded the Fenner Prize in 2012 by the Australian Society for Microbiology for her distinguished contributions to research in Microbiology.

Her current areas of interest include discovering a new HIV drug class using fragment-based drug design and understanding the role of the genital microbiota and their metabolites on adverse sexual (e.g. HIV) and reproductive health outcomes. She also has an interest in bat retroviruses and restriction factors.

Major research findings include discovering that a metabolite produced by optimal vaginal microbiota has potent HIV virucidal activity and immune modulatory effects on cervicovaginal epithelial cells that could explain in part why optimal vaginal lactobacilli are associated with decreased susceptibility to HIV (US Patent awarded in 2017).

Discovered new building blocks for drugs that target the HIV reverse transcriptase (RT) by mechanisms distinct to antiretrovirals used for HIV treatment and prevention as well as mutations in HIV RT that confer resistance to antiretroviral drugs which are incorporated in genotyping algorithms for predicting HIV drug resistance.

Played major roles in the preclinical development of microbicides to prevent the sexual transmission of HIV and the completion of a phase I clinical study (SPL7013-003) to determine the retention of the dendrimer microbicide VivaGel after vaginal dosing in healthy women.

Discovered that bats, which represent one of three significant reservoirs for deadly zoonotic viruses, encode APOBEC3, a major class of intrinsic antiviral genes, that are the most numerous and diverse of any mammal reported to date.

She developed a yeast two-hybrid assay for studying the interaction between the two subunits of the RT enzyme, which was patented. This led to the discovery that potent nonnucleoside RT inhibitors (NNRTIs) enhance RT subunit interaction and can unexpectedly affect the late stages of HIV replication.

Appointments

• 2019: Associate Editor, Viruses
• 2018: Adjunct Professor, Monash University
• 2017: President Australasian Virology Society
• 2017: Executive Member, Australian Centre for HIV and Hepatitis Virology Research
• 2017: Member, National Examinations and Qualifications Board, Australian Society for Microbiology
• 2017: Honorary Professor, Melbourne University
• 2015: Vice President, Australasian Virology Society
• 2014: Editorial Board, Antimicrobial Agents and Chemotherapy
• 2013: Principal for Sexual and Reproductive Health, Burnet Institute
• 2012 – 2017: Member Judging Panel, Premiers Award for Health and Medical Research
• 2011: ASMR representative on the Premiers Award for Health and Medical Research judging panel.
• 2011: Academic Editor, PLoS ONE
• 2009: Principal Burnet Fellow, Burnet Institute
• 2009: Editorial Board, AIDS Research and Human Retroviruses
• 2008: Adjunct Associate Professor, Department of Microbiology, Monash University
• 2007: Editorial Board, The Open Microbiology Journal
• 2005: Editorial Board, Current HIV Research
• 2005: Honorary Senior Lecturer, Department of Microbiology, Monash University
• 2005-2007: Director, ASMR National Committee
• 2005-2010: ASMR Liaison to the Premiers Award for Health and Medical Research
• 2004-2005: Victorian State Convenor, ASMR Medical Research Week
• 2004: Member, National Centre for HIV Epidemiology and Clinical Research Antiretroviral Working Group.
• 2002: Committee Member ASMR MRW, Victorian Branch

Positions

• 2017: Head of Life Sciences, Burnet Institute
• 2017: co-Head, Eliminate HIV
• 2017: NHMRC Senior Research Fellow
• 2011: Head, Retroviral Biology and Antivirals Laboratory, Burnet Institute
• 2009: NHMRC Senior Research Fellow
• 2003-2010: Head, Molecular Interactions Group, Burnet Institute
• 1997-2001: CJ Martin Postdoctoral Fellow (Laboratory of Professor Stephen P Goff) Columbia University, Department of Biochemistry and Molecular Biophysics, Howard Hughes Medical Institute, New York, USA.

Qualifications

• 1997: PhD in Microbiology, Monash University, Victoria, Australia
• 1984: BSc (Hons), Monash University, Australia

Awards

• 2012: Fenner Award, Burnet Institute
• 2012: Fenner Award, Australian Society for Microbiology
• 2011: Fellow of the Australian Society for Microbiology (FASM)
• 2009: NHMRC Senior Research Fellowship
• 2008: Nick Crofts Publication Award for top rated publication from the Burnet Institute in 2007
• 2004: CASS Foundation Travel Grant
• 2003: NHMRC RD Wright Career Development Award
• 1997: NHMRC CJ Martin Postdoctoral Fellowship
• 1995: First Prize, Best Oral Presentation, 7th Annual Conference ASHM, Coolum, Australia

Projects (15)

Current (10)

• 

  A novel gel for targeting vaginal inflammation to prevent HIV transmission

• 

  Antimicrobial and immune modulatory effects of vaginal microbiota metabolites

• 

  Bat viruses and antiviral immunity❗PhD Projects Available

• 

  Burnet Microbiome Initiative

• 

  Characterisation of retroviruses in bats

• 

  Development of hydrogel based intravaginal drug delivery device

• 

  EVE-M

• 

  Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility

• 

  Intrinsic host antiviral activity against pathogenic viruses

• 

  Targeting novel sites on reverse transcriptase for HIV treatment and prevention

Publications (112)

2022 (6)

• Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial.
  McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, Bryant M, Garlick J, Paterson A, Lee SJ, O'Bryan J, Hearps A, Tachedjian G, Pinskier H, Phillips C, Garrow S, Pinskier N, Melvin R, Blakeway L, Wisniewski JA, Byers S, Badoordeen GZ, Pereira S, Pragastis K, Trubiano JA, Chua KYL, Kainer M, Molton JS, Gardiner BJ, Pierce AB, Cheng A, Rogers BA, Peleg AY
  EClinicalMedicine. 2022 Dec; 54:101703
• Unique evolution of antiviral tetherin in bats.
  Hayward JA, Tachedjian M, Johnson A, Irving AT, Gordon TB, Cui J, Nicolas A, Smith I, Boyd V, Marsh GA, Baker ML, Wang LF, Tachedjian G
  J Virol. 2022 Sep; 96(20):e01152-22
• A project to validate the GLU test for preterm birth prediction in First Nations women.
  Brown K, Unger HW , Peel M , Doherty DA , Lee M , Kujawa A , Holder S , Tachedjian G, Masson L , Thorn JC, Newnham JP, Payne MS
  Microbiol Austr. 2022 Sep; 43(3):130-134
• Lactic acid from vaginal microbiota enhances cervicovaginal epithelial barrier integrity by promoting tight junction protein expression.
  Delgado-Diaz DJ, Jesaveluk B, Hayward JA, Tyssen D, Alisoltani A, Potgieter M, Bell L, Ross E, Iranzadeh A, Allali I, Dabee S, Barnabas S, Gamieldien H, Blackburn JM, Mulder N, Smith SB, Edwards VL, Burgener AD, Bekker LG, Ravel J, Passmore JS, Masson L, Hearps AC, Tachedjian G
  Microbiome. 2022 Aug; 10(1):141
• The Impact of Over-The-Counter Lactic Acid Containing Vaginal Gels on the Integrity and Inflammatory State of the Vaginal Epithelium in vitro.
  Tyssen D, Hearps AC, Guntur K, Masson L, Cook S, Moulton SE, Ravel J, Bradshaw CS, Ayehunie S, Tachedjian G
  Front Reprod Health. 2022 Jun; 4:915948
• A summary of the sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention and Treatment.
  Sherrill-Mix S, Yang M, Aldrovandi GM, Brenchley J, Bushman F, Collman R, Dandekar S, Klatt NR, Lagenaur LA, Landay A, Paredes R, Tachedjian G, Turpin JA, Serrano-Villar S, Lozupone C, Ghosh M
  AIDS Res Hum Retroviruses. 2022 Jan; 38(3):173-180

2021 (10)

• The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review.
  Ratten LK, Plummer EL, Bradshaw CS, Fairley CK, Murray GL, Garland SM, Bateson D, Tachedjian G, Masson L, Vodstrcil LA
  Front Cell Infect Microbiol. 2021 Nov; 11:732423
• Retroviruses of Bats: a Threat Waiting in the Wings?
  Hayward JA, Tachedjian G
  mBio. 2021 Sep
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report July Update)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Aug; Update 1:1-23
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (PUBLIC HEALTH REPORT)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Jul; June(Update 1):1-24
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 May; Update 1:1-27
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Apr; Update 1:1-24
• HERV-K Gag RNA and Protein Levels Are Elevated in Malignant Regions of the Prostate in Males with Prostate Cancer.
  Rezaei SD, Hayward JA, Norden S, Pedersen J, Mills J, Hearps AC, Tachedjian G
  Viruses. 2021 Mar; 13(3):449
• Sex is associated with the persistence of non‐optimal vaginal microbiota following treatment for bacterial vaginosis: a prospective cohort study.
  Ratten LK, Plummer EL, Murray GL, Danielewski J, Fairley CK, Garland SM, Hocking JS, Tachedjian G, Chow EPF, Bradshaw CS, Vodstrcil LA
  BJOG. 2021 Mar; 128(4):757-67
• COVID-19 Global Trends and Analyses Volume 2:- Vaccine and Viral Variants Update - COVID-19 Global Snapshots. (Public Health Report)
  Toole M, Drummer H, Tachedjian G, Umali S, Majumdar S
  Know-C19. 2021 Mar; Update 1:1-22
• Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review.
  Plummer EL, Bradshaw CS, Doyle M, Fairley CK, Murray GL, Bateson D, Masson L, Slifirski J, Tachedjian G, Vodstrcil LA
  PLoS One. 2021 Feb; 16(2):e0246953

2020 (7)

• Covid-19 Global Trends and Analysis - Volume 2: SARS-CoV-2 viral load dynamics and infectivity.
  Tachedjian G, Hearps A, Majumdar S, Toole M, Umali S
  Know-C19 Burnet Institute. 2020 Dec; Update 1(December):1-5
• A summary of the fifth annual Virology Education HIV Microbiome workshop.
  Sherrill-Mix S, Connors K, Aldrovandi GM, Brenchley J, Boucher C, Bushman F, Collman R, Dandekar S, Klatt NR, Lagenaur LA, Paredes R, Tachedjian G, Turpin JA, Landay A, Ghosh M
  AIDS Res Hum Retroviruses. 2020 Aug; 36(11):886-895
• Editorial: Interplay of Infection and Microbiome.
  Huston WM, Tachedjian G
  Front Cell Infect Microbiol. 2020 Jun; 10:304
• Tenth Scientific Biennial Meeting of the Australasian Virology Society-AVS10 2019.
  Helbig KJ, Bull RA, Ambrose R, Beard MR, Blanchard H, Böcking T, Chua B, Colmant AMG, Crosse KM, Purcell DFJ, Fraser J, Hayward JA, Hamilton ST, Husain M, MacDiarmid R, Mackenzie JM, Moseley GW, Nguyen THO, Quiñones-Mateu ME, Robinson K, Rodrigo C, Rodriguez-Andres J, Rudd PA, Werno A, White P, Young P, Speck P, Hibma M, Drummer HE, Tachedjian G
  Viruses. 2020 Jun; 12(6):E621
• The most promising treatments for COVID-19 (Updated 6th July 2020)
  Lewin S, Copolov D, Crabb B, Cuthbertson A, Doherty P, Hoy W, Kelleher A, Majumdar S, Tachedjian G
  Rapid Res Infor Forum. 2020 May
• Infectious KoRV-related retroviruses circulating in Australian bats.
  Hayward JA, Tachedjian M, Kohl C, Johnson A, Dearnley M, Jesaveluk B, Langer C, Solymosi PD, Hille G, Nitsche A, Sánchez CA, Werner A, Kontos D, Crameri G, Marsh GA, Baker ML, Poumbourios P, Drummer HE, Holmes EC, Wang LF, Smith I, Tachedjian G
  Proc Natl Acad Sci U S A. 2020 Apr; 117(7):9529–9536
• Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota.
  Delgado-Diaz DJ, Tyssen D, Hayward JA, Gugasyan R, Hearps AC, Tachedjian G
  Front Cell Infect Microbiol. 2020 Jan; 9:446

2019 (9)

• Risk of Subsequent HIV Infection Following Sexually Transmissible Infections Among Men Who Have Sex With Men.
  Harney BL, Agius PA, El-Hayek C, Fairley CK, Chow EPF, Roth N, Tee BK, Leslie D, Tachedjian G, Hellard M, Stoové M
  Open Forum Infect Dis. 2019 Oct; 6(10):ofz376
• Effects of an over-the-counter lactic-acid containing intra-vaginal douching product on the vaginal microbiota.
  van der Veer C, Bruisten SM, van Houdt R, Matser AA, Tachedjian G, van de Wijgert JHHM, de Vries HJC, van der Helm JJ
  BMC Microbiol. 2019 Jul; 19(1):168
• Oxazole-benzenesulfonamide derivatives inhibit HIV-1 reverse transcriptase interaction with cellular eEF1A and reduce viral replication.
  Rawle DJ, Li D, Wu Z, Wang L, Choong M, Lor M, Reid RC, Fairlie DP, Harris J, Tachedjian G, Poulsen SA, Harrich D
  J Virol. 2019 May; 93(12):e00239-19
• Effect of seminal plasma on functions of monocytes and granulocytes.
  Selva KJ, Juno JA, Worley MJ, Chung AW, Tachedjian G, Kent SJ, Parsons MS
  AIDS Res Hum Retroviruses. 2019 Apr; 35(6):553-556
• A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats.
  Kaminskas LM, Williams CC, Leong NJ, Chan LJ, Butcher NJ, Feeney OM, Porter CJH, Tyssen D, Tachedjian G, Ascher DB
  Eur J Pharm Biopharm. 2019 Mar; 137:218-226
• Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial.
  Vodstrcil LA, Plummer ME, Fairley CK, Tachedjian G, Law MG, Hocking JS, Worthington MK, Grant MM, Okoko N, Bradshaw CS
  Sci Rep. 2019 Mar; 9(1):3555
• The evolving facets of bacterial vaginosis: implications for HIV transmission.
  McKinnon LR, Achilles S, Bradshaw CS, Burgener A, Crucitti T, Fredricks DN, Jaspan HB, Kaul R, Kaushic C, Klatt N, Kwon DS, Marrazzo JM, Masson L, McClelland S, Ravel J, van de Wijgert JHHM, Vodstrcil LA, Tachedjian G
  AIDS Res Hum Retroviruses. 2019 Jan; 35(3):219-228
• Host and Viral Proteins Modulating Ebola and Marburg Virus Egress.
  Gordon TB, Hayward JA, Marsh GA, Baker ML, Tachedjian G
  Viruses. 2019 Jan; 11(1):e25
• Molecular Dissection of an Inhibitor Targeting the HIV Integrase Dependent Pre-Integration Complex Nuclear Import.
  Wagstaff KM, Headey S, Telwatte S, Tyssen D, Hearps AC, Thomas DR, Tachedjian G, Jans DA
  Cell Microbiol. 2019 Jan; 21(1):e12953

2018 (3)

• Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid.
  Tyssen D, Wang YY, Hayward JA, Agius PA, DeLong K, Aldunate M, Ravel J, Moench TR, Cone RA, Tachedjian G
  mSphere. 2018 Jul; 3(4):e00055-18
• Differential evolution of antiretroviral restriction factors in pteropid bats as revealed by APOBEC3 gene complexity.
  Hayward JA, Tachedjian M, Cui J, Cheng AZ, Johnson A, Baker M, Harris RS, Wang LF, Tachedjian G
  Mol Biol Evol. 2018 Mar; 35(7):1626–1637
• The implausible "in vivo" role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota.
  Tachedjian G, O'Hanlon DE, Ravel J
  Microbiome. 2018 Feb; 6(1):29

2017 (3)

• The role of lactic acid production by probiotic Lactobacillus species in vaginal health.
  Tachedjian G, Aldunate M, Bradshaw CS, Cone RA
  Res Microbiol. 2017 Apr; 168(9-10):782-792
• Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition.
  Hearps AC, Tyssen D, Srbinovski D, Bayigga L, Diaz DJD, Aldunate M, Cone RA, Gugasyan R, Anderson DJ, Tachedjian G
  Mucosal Immunol. 2017 Apr; 10(6):1480-1490
• Nonnucleoside reverse transcriptase inhibitors reduce HIV-1 virus production from latently infected resting CD4+ T cells following latency reversal.
  Zerbato JM, Tachedjian G, Sluis-Cremer N
  Antimicrob Agents Chemother. 2017 Feb; 61(3):e01736-16

2016 (7)

• Increasing Prevalence of Synonymous Mutations K65K and K66K in HIV-1 subtype B reverse transcriptase.
  Telwatte S, Brumme CJ, Hearps AC, Latham CF, Hayward JA, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G
  AIDS. 2016 Sep; 30(18):2787-2793
• Why Do We Need New Drug Classes for HIV Treatment and Prevention?
  Waheed AA, Tachedjian G
  Curr Top Med Chem. 2016 May; 16(12):1343-1349
• Editorial: Current and Emerging Drug Targets for Human Immunodeficiency Virus.
  Waheed AA, Tachedjian G
  Curr Top Med Chem. 2016 Apr; 16(10):1072-1073
• Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
  Latham CF, La J, Tinetti RN, Chalmers DK, Tachedjian G
  Curr Top Med Chem. 2016 Mar; 16(10):1135-1153
• Contraction of the type I IFN locus and unusual constitutive expression of IFN-alpha in bats.
  Zhou P, Tachedjian M, Wynne JW, Boyd V, Cui J, Smith I, Cowled C, Ng JH, Mok L, Michalski WP, Mendenhall IH, Tachedjian G, Wang LF, Baker ML
  Proc Natl Acad Sci U S A. 2016 Feb; 113(10):2696-2701
• High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo.
  Lloyd SB, Lichtfuss M, Amarasena TH, Alcantara S, De Rose R, Tachedjian G, Alinejad-Rokny H, Venturi V, Davenport MP, Winnall WR, Kent SJ
  Virology. 2016 Feb; 492:1-10
• Mechanisms of HIV transmission in Depo-Provera users: The likely role of hypoestrogenism.
  Hickey M, Marino JL, Tachedjian G
  JAIDS. 2016 Jan; 71(1):1-7

2015 (5)

• Bats and Rodents Shape Mammalian Retroviral Phylogeny.
  Cui J, Gilda Tachedjian G, Wang L-F
  Sci Rep. 2015 Nov; 5:16561
• Bats and Reverse Transcribing RNA and DNA Viruses (Book Chapter)
  Tachedjian G, Hayward JA, Cui J
  in Bats and Viruses: A New Frontier of Emerging Infectious Diseases, Editors LF Wang and C Cowled, Published by Wiley. 2015 Jul; Chapter 7 :177-202
• Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis.
  Aldunate M, Srbinovski D, Hearps AC, Latham CF, Ramsland PA, Gugasyan R, Cone RA, Tachedjian G
  Front Physiol. 2015 Jun; 6:164
• Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
  La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G
  PNAS. 2015 May; 112(22):6979-6984
• Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.
  Telwatte S, Hearps AC, Johnson A, Latham CF, Moore K, Agius P, Tachedjian M, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G
  Nucleic Acids Res. 2015 Mar; Epub ahead of print

2013 (7)

• HIV-1 Infection of T Cells and Macrophages Are Differentially Modulated by Virion-Associated Hck: A Nef-Dependent Phenomenon.
  Cornall A, Mak J, Greenway A, Tachedjian G
  Viruses. 2013 Sep; 5(9):2235-2252
• Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
  Geretti AM, Fox Z, Johnson JA, Booth C, Lipscomb J, Stuyver LJ, Tachedjian G, Baxter J, Touloumi G, Lehmann C, Owen A, Phillips A; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
  PLoS One. 2013 Jul; 8(7):e69266
• The seventh (and last?) International Microbicides Conference: from discovery to delivery.
  McGregor S, Tachedjian G, Haire BG, Kaldor JM
  Sex Health. 2013 May; 10(3):240-245
• Vaginal concentrations of lactic acid potently inactivate HIV.
  Aldunate M, Tyssen D, Johnson A, Zakir T, Sonza S, Moench T, Cone R, Tachedjian G
  J Antimicrob Chemother. 2013 May; 68(9):2015-25
• The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes.
  Gray LR, Tachedjian G, Ellett AM, Roche MJ, Cheng WJ, Guillemin GJ, Brew BJ, Turville SG, Wesselingh SL, Gorry PR, Churchill MJ
  PLoS One. 2013 Apr; 8(4):e62196
• Identification of diverse full-length endogenous betaretroviruses in megabats and microbats.
  Hayward JA, Tachedjian M, Cui J, Field H, Holmes EC, Wang LF, Tachedjian G
  Retrovirology. 2013 Mar; 10(1):35
• No association between XMRV or related gammaretroviruses in Australian prostate cancer patients.
  Rezaei SD, Hearps AC, Mills J, Pedersen J, Tachedjian G
  Virol J. 2013 Jan; 10(1):20

2012 (7)

• Host-pathogen interactions of retroviruses.
  Waheed AA, Brass AL, Gummuluru S, Tachedjian G
  Mol Biol Int. 2012 Oct; 2012:648512
• Biology of Mucosally Transmitted Sexual Infection - Translating the Basic Science Into Novel HIV intervention: A Workshop Summary.
  Purcell D, Cunningham A, Turville S, Tachedjian G, Landay A
  AIDS Res Hum Retroviruses. 2012 Sep; ;28(11):1389-1396
• Phosphatidylethanolamine-binding is a conserved feature of cyclotide-membrane interactions.
  Henriques ST, Huang YH, Castanho MA, Bagatolli LA, Sonza S, Tachedjian G, Daly NL, Craik DJ
  J Biol Chem. 2012 Aug; 287(40):33629-33643
• N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine.
  Yap SH, Herman BD, Radzio J, Sluis-Cremer N, Tachedjian G
  J Acquir Immune Defic Syndr. 2012 Jun; 61(12):153-157
• Identification of diverse groups of endogenous gammaretroviruses in mega and microbats.
  Cui J, Tachedjian G, Tachedjian M, Holmes EC, Zhang S, Wang LF
  J Gen Virol. 2012 Jun; 93(Pt 9):2037-2045
• Discovery of retroviral homologs in bats: implications for the origin of mammalian gammaretroviruses.
  Cui J, Tachedjian M, Wang L, Tachedjian G, Wang LF, Zhang S
  J Virol. 2012 Apr; 86(8):4288-4293
• Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle.
  Gorzin AA, Ramsland PA, Tachedjian G, Gowans EJ
  J Viral Hepat. 2012 Mar; 19(3):189-198

2011 (3)

• SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
  Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G
  PLoS One. 2011 Sep; 6(9):e24095
• Decoding the membrane activity of the cyclotide kalata B1: the importance of phosphatidylethanolamine phospholipids and lipid organization on hemolytic and anti-HIV activities.
  Henriques ST, Huang YH, Rosengren KJ, Franquelim HG, Carvalho FA, Johnson A, Sonza S, Tachedjian G, Castanho MA, Daly NL, Craik DJ
  J Biol Chem. 2011 Jul; 286(27):24231-24241
• Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
  Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G
  Antiviral Res. 2011 Jun; 90(3):195-199

2010 (4)

• Structure activity relationship of dendrimer microbicides with dual action antiviral activity.
  Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G
  PLoS One. 2010 Aug; 5(8):e12309
• Ubisol-Aqua: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model.
  Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ
  Curr HIV Res. 2010 Apr; 8(3):232-239
• N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
  Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N
  AIDS. 2010 Mar; 24(5):659-667
• N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
  Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G
  AIDS. 2010 Jan; 24(2):317-319

2009 (4)

• Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay.
  van Rooijen LB, Greengrass V, Morris LM, Plate MM, Gouillou M, Tachedjian G, Sluis-Cremer N, Hearps AC, Crowe SM
  J Acquir Immune Defic Syndr. 2009 Dec; 52(4):527-529
• Maturation of the HIV reverse transcription complex: putting the jigsaw together.
  Warrilow D, Tachedjian G, Harrich D
  Rev Med Virol. 2009 Nov; 19(6):324-337
• Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.
  Sonza S, Johnson A, Tyssen D, Spelman T, Lewis GR, Paull JR, Tachedjian G
  Antimicrob Agents Chemother. 2009 Aug; 53(8):3565-3568
• The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
  Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N
  J Virol. 2009 Apr; 83(8):3826-3833

2008 (2)

• Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
  Sluis-Cremer N, Tachedjian G
  Virus Res. 2008 Jun; 134(1-2):147-156
• Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.
  Figueiredo A, Zelina S, Sluis-Cremer N, Tachedjian G
  Curr HIV Res. 2008 Mar; 6(2):130-137

2007 (5)

• 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.
  Maher L, Tachedjian G, Hoy JF, Millwood I, Guy RJ, Walsh NM, Zaunders JJ, Jaworowski A, Kaldor JM
  Med J Aust. 2007 Dec; 187(11-12):610-612
• N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
  Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G
  PLoS Med. 2007 Dec; 4(12):e335
• Targeting human immunodeficiency virus type 1 assembly, maturation and budding.
  Wapling J, Srivastava S, Shehu-Xhilaga M, Tachedjian G
  Drug Target Insights. 2007 Jul; 2:159-182
• Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.
  Nissley DV, Radzio J, Ambrose Z, Sheen CW, Hamamouch N, Moore KL, Tachedjian G, Sluis-Cremer N
  Biochem J. 2007 May; 404(1):151-157
• Alteration of the proline at position 7 of the HIV-1 spacer peptide p1 suppresses viral infectivity in a strain dependent manner.
  Hill MK, Bellamy-McIntyre A, Vella LJ, Campbell SM, Marshall JA, Tachedjian G, Mak J
  Curr HIV Res. 2007 Jan; 5(1):69-78

2006 (2)

• Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
  Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G
  PLoS Pathog. 2006 Nov; 2(11):e119
• Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target.
  Srivastava S, Sluis-Cremer N, Tachedjian G
  Curr Pharm Des. 2006 Jan; 12(15):1879-1894

2005 (7)

• Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.
  Wapling J, Moore KL, Sonza S, Mak J, Tachedjian G
  J Virol. 2005 Aug; 79(16):10247-10257
• Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase.
  Tachedjian G, Radzio J, Sluis-Cremer N
  Proteins. 2005 Jul; 60(1):5-13
• Analysis of the contribution of reverse transcriptase and integrase proteins to retroviral RNA dimer conformation.
  Buxton P, Tachedjian G, Mak J
  J Virol. 2005 May; 79(10):6338-6348
• Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring.
  Greengrass VL, Turnbulll SP, Hocking J, Dunne AL, Tachedjian G, Corrigan GE, Crowe SM
  Curr HIV Res. 2005 Apr; 3(2):183-190
• Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation.
  Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N
  FEBS Lett. 2005 Jan; 579(2):379-384
• The packaging and maturation of the HIV-1 Pol proteins.
  Hill M, Tachedjian G, Mak J
  Curr HIV Res. 2005 Jan; 3(1):73-85
• Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.
  Shehu-Xhilaga M, Tachedjian G, Crowe SM, Kedzierska K
  Curr Med Chem. 2005 Jan; 12(15):1705-1719

2004 (1)

• Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors.
  Tachedjian G, Mijch A
  Sex Health. 2004 Jan; 1(2):81-89

2003 (2)

• The effect of NNRTIs on HIV reverse transcriptase dimerization.
  Tachedjian G, Goff SP
  Curr Opin Investig Drugs. 2003 Aug; 4(8):966-973
• Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization.
  Gilda Tachedjian, Hans-Erik G Aronson, Martha de los Santos, Jas Seehra, John M McCoy, Stephen P Goff
  J Mol Biol. 2003 Feb; 326(2):381-396

2002 (1)

• Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.
  Sluis-Cremer N, Tachedjian G
  Eur J Biochem. 2002 Nov; 269(21):5103-5111

2001 (1)

• Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
  G Tachedjian, M Orlova, S G Sarafianos, E Arnold, S P Goff
  Proc Natl Acad Sci U S A. 2001 Jun; 98(13):7188-7193

2000 (1)

• Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.
  G Tachedjian, H E Aronson, S P Goff
  Proc Natl Acad Sci U S A. 2000 Jun; 97(12):6334-6339

1998 (2)

• Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.
  Tachedjian G, French M, Mills J
  Antimicrob Agents Chemother. 1998 Nov; 42(11):3038-3043
• Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.
  Tachedjian G, Mellors JW, Bazmi H, Mills J
  AIDS Res Hum Retroviruses. 1998 Aug; 14(12):1059-1064

1997 (1)

• Antiviral activity of DG-35-VIII, a potent inhibitor of the protease of human immunodeficiency virus.
  Grobelny D, Chen Q, Tyssen D, Tachedjian G, Sebire K, Buchanan L, Birch C
  Antiviral Chem Chemother. 1997 Mar; 8(2):99-106

1996 (2)

• An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
  Hooker DJ, Tachedjian G, Solomon AE, Gurusinghe AD, Land S, Birch C, Anderson JL, Roy BM, Arnold E, Deacon NJ
  J Virol. 1996 Nov; 70(11):8010-8018
• Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
  Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J
  J Virol. 1996 Oct; 70(10):7171-7181

1995 (2)

• Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.
  Tachedjian G, Hooker DJ, Gurusinghe AD, Bazmi H, Deacon NJ, Mellors J, Birch C, Mills J
  Virology. 1995 Sep; 212(1):58-68
• Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
  Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ
  J Med Virol. 1995 Jul; 46(3):238-243

1994 (1)

• Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient.
  Tachedjian G, Hoy J, McGavin K, Birch C
  J Med Virol. 1994 Feb; 42(2):207-211

1993 (1)

• Cellular topoisomerase I activity associated with HIV-1.
  Jardine D, Tachedjian G, Locarnini S, Birch C
  AIDS Res Hum Retroviruses. 1993 Dec; 9(12):1245-1250

1992 (1)

• Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
  Birch CJ, Tyssen DP, Tachedjian G, Doherty R, Hayes K, Mijch A, Lucas CR
  J Infect Dis. 1992 Jul; 166(1):108-112

1990 (3)

• Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
  Birch CJ, Tachedjian G, Doherty RR, Hayes K, Gust ID
  J Infect Dis. 1990 Sep; 162(3):731-734
• Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1
  Tachedjian G, Tyssen D, Locarnini S, Gust I, Birch C
  Antivir Chem Chemother. 1990 Jul; 12:131-138
• Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds.
  Civitico G, Wang YY, Luscombe C, Bishop N, Tachedjian G, Gust I, Locarnini S
  J Med Virol. 1990 Jun; 31(2):90-97

1988 (2)

• In vitro effectiveness of a combination of zidovudine and ansamycin against human immunodeficiency virus.
  C Birch, G Tachedjian, C R Lucas, I Gust
  J Infect Dis. 1988 Oct; 158(4):895
• Diethanolamine fusidate has no in-vitro activity against the human immunodeficiency virus.
  C Birch, G Tachedjian, I Gust
  Med J Aust. 1988 Aug; 149(4):224-225

News Articles (52)

2022 (4)

• 2022 in Review: July to December
• Meet the female powerhouses behind HIV research at Burnet
• A new way lactic acid can reduce a woman’s risk of getting an STI
• Burnet teams up with Monash and BioCurate to develop novel HIV antivirals

2021 (4)

• Statement of support of TGA
• COVID-19 Global Update: 1-31 May 2021
• COVID-19 Global Update: Vaccines and Variants
• COVID-19 Timeline: How Science Matters

2020 (6)

• 2020 in Review: January to June
• Female HIV preventative project receives international support
• Burnet a knowledge hub for COVID-19
• New virus in bats linked to AIDS-like disease decimating koalas
• Burnet's EVE-M team celebrating the International Day of Women and Girls in Science
• EVE-M: Transforming women's health

2019 (5)

• ACH2 grants a terrific outcome
• 25 ways we're working to eliminate HIV
• MRFF funding for ambitious women's health project
• Seeking clarity on BV
• Around the microbiome in 30 minutes

2018 (8)

• NHMRC grants for Burnet research
• ACH2 grants a fabulous outcome
• World AIDS Day 2018: Everybody Counts
• HIV research accelerated
• Burnet at AIDS 2018!
• Professor Tachedjian chairs session at AIDS 2018
• Burnet research reveals power of bats’ antiviral genes
• ACH2 grants for Burnet research

2017 (6)

• Burnet's leaders in virology
• Long, complex road ahead in microbiome research
• Lactic acid's role in protecting women at risk of HIV
• New funding boost to eliminate HIV in Victoria
• Protection for women at high risk of HIV
• Drug resistance a growing threat

2016 (5)

• NHMRC grants for Burnet researchers
• NHMRC grants for Burnet research
• IWD reflections
• Bats offer new clues to immunity
• Focus on drug-resistant HIV

2015 (4)

• 2015 in Review: January - June
• Governor visits Burnet
• HIV research attracts Nature's interest
• Burnet discovery of building blocks for new drug classes to prevent and treat HIV

2014 (3)

• 2014 In Review: July - December
• Burnet Institute researchers acknowledged in NHMRC funding round
• AIDS 2014: Conversation Hour at Burnet Institute

2013 (2)

• Congratulations to Burnet's NHMRC grant recipients
• Female-controlled strategies for HIV prevention

2012 (4)

• Gilda Tachedjian delivers 2012 Fenner Lecture
• Burnet virologist awarded the ASM's 2012 Frank Fenner Award
• 'Outstanding' young researcher wins Burnet award
• Microbicides: enabling women to protect themselves against HIV

2011 (1)

• Burnet NHMRC grant recipients 2012